SCHEMBL258670

SCHEMBL258670

CN(N)C1CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3229473 0.97 ADH1A (0.44)
Hydrochloric Acid SCHEMBL27925623 0.97 ADH1A (0.44)
SCHEMBL389800 0.97
SCHEMBL16573384 0.94
SCHEMBL722434 0.83
Hydrochloric Acid SCHEMBL4166672 0.80
Trifluoroacetic Acid SCHEMBL31419183 0.78 ALDH1A1 (0.38)
SCHEMBL23072500 0.73 ADH1A (0.50)
SCHEMBL24914755 0.73 ADH1A (0.50)
SCHEMBL22212617 0.73 ADH1A (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101646656-B Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI AVENTIS SPA 2013-08-14 CN claimed
EP-2597955-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME OncoTherapy Science, Inc. (JP) 2013-06-05 EP claimed
WO-2012016082-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2012-02-02 WO claimed
CN-101646656-A Pyrimidine hydrazide compounds as the PGDS inhibitor SANOFI AVENTIS FR 2010-02-10 CN claimed
EP-0918052-B1 Improved polymeric mdi color BAYER AG (US) 2003-05-28 EP claimed
US-5942151-A PREVENTING THE DISCOLORATION OF PRODUCING POLYMETHYLENEPOLYPHENYLENE POLYISOCYANATE BY ADDING AN ADDITIVE HYDRAZINE OR A HYDRAZINE DERIVATIVE BAYER CORPORATION (US) 1999-08-24 US claimed
EP-0918052-A1 Improved polymeric mdi color Bayer Corporation (US) 1999-05-26 EP claimed
US-11992811-B2 Crosslinked hollow-fibre membranes and new process for manufacturing the same EVONIK OPERATIONS GMBH (DE) 2024-05-28 US disclosed
WO-2023081400-A9 DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) 2023-06-01 WO disclosed
WO-2023081400-A1 DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) 2023-05-11 WO disclosed
EP-3959251-A1 LATENT REACTIVE ADHESIVE PREPARATIONS Covestro Intellectual Property GmbH & Co. KG (DE) 2022-03-02 EP disclosed
US-20210394125-A1 CROSSLINKED HOLLOW-FIBRE MEMBRANES AND NEW PROCESS FOR MANUFACTURING THE SAME EVONIK OPERATIONS GMBH (DE) 2021-12-23 US disclosed
EP-3756464-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-12-30 EP disclosed
US-5462960-A Very good affinity for cannabinoid receptor; having psycho-tropic activity SANOFI (FR) 1995-10-31 US disclosed
EP-0658546-A1 Novel 3-pyrazolecarboxamide derivatives with cannabinoid receptor affinity SANOFI (FR) 1995-06-21 EP disclosed
EP-0328274-A1 Pt (IV) complexes JOHNSON MATTHEY, INC., (US) 1989-08-16 EP disclosed
EP-0000016-B1 PROCESS FOR THE PREPARATION OF ALLOPHANATES-SUBSTITUTED POLYISOCYANATES AND THEIR USE IN THE MANUFACTURE OF POLYURETHANE PRODUCTS BAYER AG (DE) 1980-07-23 EP disclosed
US-4210671-A Abietamide derivatives, their production and use ENOMOTO HIROSHI (JP) 1980-07-01 US disclosed
US-4177342-A FROM CARBAMATE(URETHANE)-CONTAINING ALCOHOLS AND POLYISOCYANATES BAYER AKTIENGESELLSCHAFT (DE) 1979-12-04 US disclosed
EP-0000016-A1 Process for the preparation of allophanates-substituted polyisocyanates and their use in the manufacture of polyurethane products BAYER AG (DE) 1978-12-20 EP disclosed